The P/E ratio for Rigel Pharmaceuticals stock stands at 1.5 as of Jun 3, 2026. The calculation is based on the latest EPS of $20.23 and the stock price of $30.3 per share. A decrease of 47% has been observed in the PE ratio compared to its average of 2.8 of the past four quarters.
Over the last two years, the average PE ratio of Rigel Pharmaceuticals has been 15.32. The current 1.5 price-to-earnings ratio is 90% less than the historical average. Analyzing the last two years, RIGL's PE ratio reached its highest point in the Sep 2024 quarter at 70.35, with a price of $16.18 and an EPS of $0.23. The Mar 2026 quarter saw the lowest point at 1.34, with a price of $27.04 and an EPS of $20.23.
Maximum annual decrease: -87.64% in 2025
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 2.1 | -87.64% | $42.83 | $20.4 |
| 2024 | 16.99 | N/A | $16.82 | $0.99 |
| 2023 | N/A | N/A | $14.5 | -$1.44 |
| 2022 | N/A | N/A | $15 | -$3.44 |
| 2021 | N/A | N/A | $26.5 | -$1.1 |
| 2020 | N/A | N/A | $35 | -$1.8 |
| 2019 | N/A | N/A | $21.4 | -$4 |
| 2018 | N/A | N/A | $23 | -$4.4 |
| 2017 | N/A | N/A | $38.8 | -$6.2 |
| 2016 | N/A | N/A | $23.8 | -$7.3 |
| 2015 | N/A | N/A | $30.3 | -$5.8 |
| 2014 | N/A | N/A | $22.7 | -$10.4 |
| 2013 | N/A | N/A | $28.5 | -$10.2 |
| 2012 | N/A | N/A | $65 | -$13.2 |
| 2011 | N/A | N/A | $78.9 | -$13.6 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 1.34 | -36.19% | $27.04 | $20.23 |
| Dec 2025 | 2.1 | -53.13% | $42.83 | $20.4 |
| Sep 2025 | 4.48 | 31.38% | $28.33 | $6.33 |
| Jun 2025 | 3.41 | -60.21% | $18.73 | $5.49 |
| Mar 2025 | 8.57 | -49.56% | $17.99 | $2.1 |
| Dec 2024 | 16.99 | -75.85% | $16.82 | $0.99 |
| Sep 2024 | 70.35 | N/A | $16.18 | $0.23 |
| Jun 2024 | N/A | N/A | $8.22 | -$0.81 |
| Mar 2024 | N/A | N/A | $14.8 | -$1.13 |
| Dec 2023 | N/A | N/A | $14.5 | -$1.44 |
| Sep 2023 | N/A | N/A | $10.8 | -$1.45 |
| Jun 2023 | N/A | N/A | $12.9 | -$2.22 |
| Mar 2023 | N/A | N/A | $13.2 | -$2.64 |
| Dec 2022 | N/A | N/A | $15 | -$3.44 |
| Sep 2022 | N/A | N/A | $11.8 | -$4.9 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
RIGL's current PE ratio is under its 3, 5 and 10-year averages.
Rigel Pharmaceuticals's price to earnings (P/E) of 1.5 is lower than the Healthcare sector and the industry average. Looking at the Healthcare sector average of 23.02, Rigel Pharmaceuticals's price to earnings (P/E) is 93% lower.
When compared to its peer stocks AZN and AMGN, RIGL's PE ratio is lower.
| Stock name | PE ratio | Market cap |
|---|---|---|
| RIGL Rigel Pharmaceuticals Inc | 1.49 | $559.5M |
| AMGN Amgen Inc | 23.87 | $186.56B |
| XOMA XOMA Corp | 25.72 | $532.24M |
| AZN Astrazeneca plc | 27.09 | $281.59B |
RIGL stock has a price to earnings ratio of 1.5 as of Jun 3, 2026.
The 3-year average PE ratio for RIGL stock is 15.32.
The 5-year average PE ratio for RIGL stock is 15.32.
The highest quarterly PE ratio in the last two years has been 70.35 and it was in the Sep 2024 quarter.
RIGL's current price to earnings ratio is 90% below its 2-year historical average.
RIGL's stock price is trading at a lower multiple of earnings, which is why its PE ratio of 1.5 is considered low.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Jun 3, 2026), Rigel Pharmaceuticals's share price is $30.3. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $20.23. Therefore, Rigel Pharmaceuticals's price to earnings ratio for today is 1.5. PE RATIO(1.5) = STOCK PRICE($30.3) / TTM EPS($20.23)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.